SEC Form 4Coverage since Aug 15, 2025Open-market trades only
$RAPP insider trading
Over the last 12 months, Rapport Therapeutics insiders reported no purchases and 36 sales totaling $41.7M across SEC Form 4 filings. 92% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $41.7M 36 events
- Events · 12m
- 36 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 92% of events, not dollars
Side
Price · $RAPP · 3Mvia TradingView
Top insiders · 12m
Ceesay AbrahamChief Executive Officer16× · $6.0M
Yeleswaram KrishnaswamyChief Development Officer7× · $4.5M
Bredt DavidChief Scientific Officer6× · $1.4M
Gault CherylChief Operating Officer4× · $906K
Third Rock Ventures V, L.P.—3× · $29.0M
All insider trades
44 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 8,210 | $45.61 | $374K | -1.8% | plan · 2 tranches |
| Aug 25, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 18,921 | $49.57 | $938K | -3.9% | plan |
| Aug 25, 2026 | Yeleswaram KrishnaswamyChief Development Officer · O | ▼ Sale | 50,160 | $50.47 | $2.5M | -20.4% | plan · 3 tranches |
| Aug 19, 2026 | Yeleswaram KrishnaswamyChief Development Officer · O | ▼ Sale | 404 | $49.9 | $20K | -0.2% | plan |
| Aug 11, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 51,499 | $47.25 | $2.4M | -9.6% | plan · 5 tranches |
| Jul 27, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 2,210 | $42.11 | $93K | -0.4% | plan · 2 tranches |
| Jul 14, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 8,210 | $40 | $328K | -1.5% | plan · 2 tranches |
| Jun 30, 2026 | Gault CherylChief Operating Officer · O | ▼ Sale | 10,000 | $41.58 | $416K | -6.3% | plan · 4 tranches |
| Jun 29, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 8,220 | $39.83 | $327K | -1.5% | plan · 2 tranches |
| May 26, 2026 | Third Rock Ventures V, L.P.10% | ▼ Sale | 18,572 | $40.05 | $744K | -0.3% | plan |
| May 8, 2026 | Third Rock Ventures V, L.P.10% | ▼ Sale | 276,513 | $40.12 | $11.1M | -4.1% | plan · 2 tranches |
| Apr 17, 2026 | Third Rock Ventures V, L.P.10% | ▼ Sale | 426,005 | $40.32 | $17.2M | -6% | plan |
| Apr 17, 2026 | Yeleswaram KrishnaswamyChief Development Officer · O | ▼ Sale | 20,225 | $39.99 | $809K | -7.6% | plan |
| Apr 14, 2026 | Yeleswaram KrishnaswamyChief Development Officer · O | ▼ Sale | 19,865 | $35.03 | $696K | -6.9% | plan · 3 tranches |
| Apr 8, 2026 | Yeleswaram KrishnaswamyChief Development Officer · O | ▼ Sale | 360 | $34.9 | $13K | -0.1% | plan |
| Mar 30, 2026 | Gault CherylChief Operating Officer · O | ▼ Sale | 10,000 | $28.19 | $282K | -5.9% | plan · 2 tranches |
| Mar 25, 2026 | Yeleswaram KrishnaswamyChief Development Officer · O | ▼ Sale | 10,115 | $29.99 | $303K | -3.4% | plan |
| Mar 5, 2026 | Gault CherylChief Operating Officer · O | ▼ Sale | 2,014 | $28.93 | $58K | -1.2% | — |
| Feb 18, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,083 | $29.36 | $149K | -19.7% | plan · 2 tranches · indirect |
| Feb 18, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,833 | $29.34 | $171K | -1% | plan · 2 tranches |
| Feb 17, 2026 | Bredt DavidChief Scientific Officer · O | ▼ Sale | 8,500 | $29.02 | $247K | -2.1% | plan · 3 tranches |
| Jan 20, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,083 | $26.11 | $133K | -16.5% | plan · indirect |
| Jan 20, 2026 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,833 | $26.12 | $152K | -1% | plan |
| Jan 15, 2026 | Bredt DavidChief Scientific Officer · O | ▼ Sale | 8,500 | $26.84 | $228K | -2.1% | plan · 2 tranches |
| Dec 31, 2025 | Bredt DavidChief Scientific Officer · O | ▼ Sale | 6,567 | $30.05 | $197K | -1.6% | — |
| Dec 31, 2025 | Yeleswaram KrishnaswamyChief Development Officer · O | ▼ Sale | 2,840 | $30.05 | $85K | -0.9% | — |
| Dec 17, 2025 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,083 | $29.63 | $151K | -14.1% | plan · 3 tranches · indirect |
| Dec 17, 2025 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,833 | $29.64 | $173K | -1% | plan · 3 tranches |
| Dec 15, 2025 | Bredt DavidChief Scientific Officer · O | ▼ Sale | 8,500 | $30.02 | $255K | -2.1% | plan · 2 tranches |
| Nov 26, 2025 | Gault CherylChief Operating Officer · O | ▼ Sale | 5,000 | $30.1 | $150K | -2.8% | plan |
| Nov 17, 2025 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,083 | $25.2 | $128K | -12.4% | plan · 2 tranches · indirect |
| Nov 17, 2025 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,833 | $25.19 | $147K | -1% | plan · 2 tranches |
| Nov 17, 2025 | Bredt DavidChief Scientific Officer · O | ▼ Sale | 8,500 | $25.19 | $214K | -2.1% | plan · 2 tranches |
| Oct 15, 2025 | Bredt DavidChief Scientific Officer · O | ▼ Sale | 8,500 | $25.79 | $219K | -2% | plan · 2 tranches |
| Oct 15, 2025 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,083 | $25.81 | $131K | -11% | plan · 2 tranches · indirect |
| Oct 15, 2025 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 5,833 | $25.81 | $151K | -1% | plan · 2 tranches |
| Sep 17, 2025 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 35,585 | $26.32 | $936K | -43.5% | plan · 2 tranches · indirect |
| Sep 17, 2025 | Ceesay AbrahamChief Executive Officer · O·D | ▼ Sale | 40,835 | $26.32 | $1.1M | -6.5% | plan · 2 tranches |
| Sep 15, 2025 | Bredt DavidChief Scientific Officer · O | ▼ Sale | 8,500 | $24.19 | $206K | -2% | plan · 2 tranches |
| Sep 12, 2025 | Huber Reid MD | ▲ Buy | 20,400 | $24.48 | $499K | — | — |
| Sep 12, 2025 | PAUL STEVEN MD | ▲ Buy | 41,666 | $24.65 | $1.0M | — | 2 tranches · indirect |
| Sep 11, 2025 | Young Wendy B.D | ▲ Buy | 3,500 | $22.6 | $79K | +58.3% | — |
| Sep 8, 2025 | Gault CherylChief Operating Officer · O | ▼ Sale | 5,000 | $38.33 | $192K | -2.8% | plan |
| Aug 15, 2025 | Bredt DavidChief Scientific Officer · O | ▼ Sale | 8,500 | $15 | $127K | -2% | plan · 2 tranches |
Every $RAPP filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Rapport Therapeutics filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RAPP feed.